Xenetic Biosciences Inc

NASDAQ XBIO

Data sourced from

and

Daily

Download Data

Xenetic Biosciences Inc Market Capitalization on June 03, 2024: USD 6.24 M

Xenetic Biosciences Inc Market Capitalization is USD 6.24 M on June 03, 2024, a 28.91% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Xenetic Biosciences Inc 52-week high Market Capitalization is USD 9.07 M on September 21, 2023, which is 45.34% above the current Market Capitalization.
Xenetic Biosciences Inc 52-week low Market Capitalization is USD 4.47 M on November 13, 2023, which is -28.44% below the current Market Capitalization.
Xenetic Biosciences Inc average Market Capitalization for the last 52 weeks is USD 5.90 M.

NASDAQ: XBIO

Xenetic Biosciences Inc

CEO	Mr. Jeffrey F. Eisenberg Esq.
IPO Date	June 30, 2014
Location	United States
Headquarters	40 Speen Street, Framingham, MA, United States, 01701
Employees	4
Sector	Healthcare
Industry	Biotechnology

Description

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Key trends